Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fabomotizole
- Development stage
- Unknown
- Lead developer
- Pharmstandard
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Fabomotizole is a small molecule anxiolytic drug developed and launched in Russia in the early 2000s, primarily under the brand name Afobazole. It is used for the treatment of anxiety disorders, neurasthenia, adjustment disorders, sleep disturbances related to anxiety, and other stress-related conditions. Unlike benzodiazepines, it does not cause sedation or muscle relaxation and has a low risk of dependence. Its mechanism of action is not fully defined but includes modulation of sigma-1 receptor (Sigma1R), reversible inhibition of monoamine oxidase A (MAO-A), agonism at melatonin MT1 receptor, antagonism at MT3 receptor (NQO2), promotion of nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF) release, as well as possible effects on GABAergic systems and serotonin receptors. Fabomotizole has demonstrated neuroprotective properties in preclinical studies and is reported to be well tolerated with few side effects[1][5][6][8].
- Brand names
- AfobazoleAfobazol
- Other names
- Obenoxazinefabomotizole dihydrochloride
02
Targets
GABRR (GABA-A receptor subunit rho)MAOA (Monoamine oxidase A)NQO2 (Ribosyldihydronicotinamide dehydrogenase [quinone])SIGMAR1 (Sigma non-opioid intracellular receptor 1)MTNR1A (MT1)
Beyond the preview
Go deeper on fabomotizole.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fabomotizole.